{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T12:04:34Z","timestamp":1742990674655,"version":"3.40.3"},"reference-count":64,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780323853019"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/bs.pmbts.2021.01.026","type":"book-chapter","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T13:47:16Z","timestamp":1614606436000},"page":"327-351","source":"Crossref","is-referenced-by-count":2,"title":["Genome editing in mucopolysaccharidoses and mucolipidoses"],"prefix":"10.1016","author":[{"given":"Hallana Souza","family":"Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edina","family":"Poletto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roselena","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Matte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme","family":"Baldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/bs.pmbts.2021.01.026_bb0010","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1590\/S1415-47572012000600006","article-title":"Mucopolysacccharidoses: from understanding to treatment, a century of discoveries","volume":"4","author":"Giugliani","year":"2012","journal-title":"Genet Mol Biol"},{"key":"10.1016\/bs.pmbts.2021.01.026_bb0015","series-title":"Gene Delivery Strategies for the Treatment of Mucopolysaccharidoses","first-page":"449","volume":"vol 11","author":"Baldo","year":"2014"},{"issue":"1","key":"10.1016\/bs.pmbts.2021.01.026_bb0020","first-page":"1","article-title":"Glycosaminoglycans in tissue engineering: a review","volume":"11","author":"Sodhi","year":"2021","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/bs.pmbts.2021.01.026_bb0025","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1590\/S1415-47572014000300003","article-title":"Guidelines for diagnosis and treatment of Hunter syndrome for clinicians in Latin America","volume":"37","author":"Giugliani","year":"2014","journal-title":"Genet Mol Biol"},{"issue":"1","key":"10.1016\/bs.pmbts.2021.01.026_bb0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/cge.13224","article-title":"Worldwide distribution of common IDUA pathogenic variants","volume":"94","author":"Poletto","year":"2018","journal-title":"Clin Genet"},{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.026_bb0035","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ymgme.2017.05.016","article-title":"Epidemiology of mucopolysaccharidoses","volume":"121","author":"Khan","year":"2017","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/bs.pmbts.2021.01.026_bb0040","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s13023-020-01608-0","article-title":"Estimated prevalence of mucopolysaccharidoses from population-based exomes and genomes","volume":"15","author":"Borges","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/bs.pmbts.2021.01.026_bb0045","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ymgme.2011.09.017","article-title":"Genetic studies in a cluster of mucopolysaccharidosis type VI patients in Northeast Brazil","volume":"104","author":"Costa-Motta","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"7","key":"10.1016\/bs.pmbts.2021.01.026_bb0050","first-page":"842","article-title":"The lysosomal storage disorders mucolipidosis type II, type III alpha\/beta, and type III gamma: update on GNPTAB and GNPTG mutations","volume":"40","author":"Velho","year":"2019","journal-title":"Hum Mutat"},{"issue":"2","key":"10.1016\/bs.pmbts.2021.01.026_bb0055","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.ejhg.5201044","article-title":"Prevalence of lysosomal storage diseases in Portugal","volume":"12","author":"Pinto","year":"2004","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.026_bb0060","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1399-0004.2007.00954.x","article-title":"Mucolipidosis II: a single causal mutation in the N-acetylglucosamine-1-phosphotransferase gene (GNPTAB) in a French Canadian founder population","volume":"73","author":"Plante","year":"2008","journal-title":"Clin Genet"},{"issue":"18","key":"10.1016\/bs.pmbts.2021.01.026_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21186812","article-title":"Mucolipidoses overview: past, present, and future","volume":"21","author":"Khan","year":"2020","journal-title":"Int J Mol Sci"},{"year":"1993","series-title":"Mucolipidosis II","author":"Leroy","key":"10.1016\/bs.pmbts.2021.01.026_bb0070"},{"year":"1993","series-title":"Mucolipidosis III Gamma","author":"Raas-Rothschild","key":"10.1016\/bs.pmbts.2021.01.026_bb0075"},{"issue":"2","key":"10.1016\/bs.pmbts.2021.01.026_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21020500","article-title":"Genome editing for mucopolysaccharidoses","volume":"21","author":"Poletto","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/bs.pmbts.2021.01.026_bb0085","first-page":"653","article-title":"Genome editing: past, present, and future","volume":"90","author":"Carroll","year":"2017","journal-title":"Yale J Biol Med"},{"issue":"4","key":"10.1016\/bs.pmbts.2021.01.026_bb0090","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ymthe.2019.01.014","article-title":"Genome editing with mRNA encoding ZFN, TALEN, and Cas9","volume":"27","author":"Zhang","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/bs.pmbts.2021.01.026_bb0095","article-title":"Next-generation CRISPR technologies and their applications in gene and cell therapy","author":"Zeballos","year":"2020","journal-title":"Trends Biotechnol"},{"key":"10.1016\/bs.pmbts.2021.01.026_bb0100","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nm.3793","article-title":"Therapeutic genome editing: prospects and challenges","volume":"21","author":"Cox","year":"2015","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/bs.pmbts.2021.01.026_bb0105","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s10545-014-9703-x","article-title":"Genistein increases glycosaminoglycan levels in mucopolysaccharidosis type I cell models","volume":"37","author":"Kingma","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/bs.pmbts.2021.01.026_bb0110","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3389\/fmolb.2020.00224","article-title":"Human iPSC-based models for the development of therapeutics targeting neurodegenerative lysosomal storage diseases","volume":"7","author":"Luciani","year":"2020","journal-title":"Front Mol Biosci"},{"key":"10.1016\/bs.pmbts.2021.01.026_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2019.101406","article-title":"Generation of a human induced pluripotent stem cell line, BRCi001-A, derived from a patient with mucopolysaccharidosis type I","volume":"36","author":"Suga","year":"2019","journal-title":"Stem Cell Res"},{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.026_bb0120","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.scr.2016.09.033","article-title":"Generation of mucopolysaccharidosis type II (MPS II) human induced pluripotent stem cell (iPSC) line from a 1-year-old male with pathogenic IDS mutation","volume":"17","author":"Varga","year":"2016","journal-title":"Stem Cell Res"},{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.026_bb0125","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.scr.2016.09.035","article-title":"Generation of human induced pluripotent stem cell (iPSC) line from an unaffected female carrier of mucopolysaccharidosis type II (MPS II) disorder","volume":"17","author":"Varga","year":"2016","journal-title":"Stem Cell Res"},{"issue":"2","key":"10.1016\/bs.pmbts.2021.01.026_bb0130","doi-asserted-by":"crossref","first-page":"82","DOI":"10.14712\/fb2016062020082","article-title":"X-chromosome inactivation analysis in different cell types and induced pluripotent stem cells elucidates the disease mechanism in a rare case of mucopolysaccharidosis type II in a female","volume":"62","author":"Reboun","year":"2016","journal-title":"Folia Biol"},{"key":"10.1016\/bs.pmbts.2021.01.026_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2019.101427","article-title":"An induced pluripotent stem cell line (TRNDi006-A) from a MPS IIIB patient carrying homozygous mutation of p.Glu153Lys in the NAGLU gene","volume":"37","author":"Huang","year":"2019","journal-title":"Stem Cell Res"},{"key":"10.1016\/bs.pmbts.2021.01.026_bb0140","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.scr.2018.10.019","article-title":"Generation of two induced pluripotent stem cells lines from a mucopolysaccharydosis IIIB (MPSIIIB) patient","volume":"33","author":"Vallejo-Diez","year":"2018","journal-title":"Stem Cell Res"},{"key":"10.1016\/bs.pmbts.2021.01.026_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2019.101408","article-title":"Generation of an induced pluripotent stem cell line (TRNDi005-A) from a mucopolysaccharidosis type IVA (MPS IVA) patient carrying compound heterozygous p.R61W and p.WT405del mutations in the GALNS gene","volume":"36","author":"Li","year":"2019","journal-title":"Stem Cell Res"},{"issue":"1","key":"10.1016\/bs.pmbts.2021.01.026_bb0150","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-34523-3","article-title":"Lysosomal and network alterations in human mucopolysaccharidosis type VII iPSC-derived neurons","volume":"8","author":"Bayo-Puxan","year":"2018","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.026_bb0155","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood-2010-05-287607","article-title":"Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome)","volume":"117","author":"Tolar","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/bs.pmbts.2021.01.026_bb0160","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.yexcr.2019.04.021","article-title":"Modelling the neuropathology of lysosomal storage disorders through disease-specific human induced pluripotent stem cells","volume":"380","author":"Kobolak","year":"2019","journal-title":"Exp Cell Res"},{"issue":"20","key":"10.1016\/bs.pmbts.2021.01.026_bb0165","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1093\/hmg\/ddy259","article-title":"Patient iPSC-derived neural stem cells exhibit phenotypes in concordance with the clinical severity of mucopolysaccharidosis I","volume":"27","author":"Swaroop","year":"2018","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/bs.pmbts.2021.01.026_bb0170","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10545-017-0108-5","article-title":"Neural cells generated from human induced pluripotent stem cells as a model of CNS involvement in mucopolysaccharidosis type II","volume":"41","author":"Rybova","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/bs.pmbts.2021.01.026_bb0175","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6978303","article-title":"Induced pluripotent stem cell derivation and ex vivo gene correction using a mucopolysaccharidosis type 1 disease mouse model","volume":"2019","author":"Miki","year":"2019","journal-title":"Stem Cells Int"},{"issue":"18","key":"10.1016\/bs.pmbts.2021.01.026_bb0180","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1093\/hmg\/ddr285","article-title":"Modeling neuronal defects associated with a lysosomal disorder using patient-derived induced pluripotent stem cells","volume":"20","author":"Lemonnier","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"8","key":"10.1016\/bs.pmbts.2021.01.026_bb0185","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3390\/cancers11081098","article-title":"Cancer cell lines are useful model systems for medical research","volume":"11","author":"Mirabelli","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/bs.pmbts.2021.01.026_bb0190","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s11011-020-00592-5","article-title":"Evidence for inflammasome activation in the brain of mucopolysaccharidosis type II mice","volume":"35","author":"Azambuja","year":"2020","journal-title":"Metab Brain Dis"},{"key":"10.1016\/bs.pmbts.2021.01.026_bb0195","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.carpath.2017.01.001","article-title":"Progressive heart disease in mucopolysaccharidosis type I mice may be mediated by increased cathepsin B activity","volume":"27","author":"Baldo","year":"2017","journal-title":"Cardiovasc Pathol"},{"issue":"January","key":"10.1016\/bs.pmbts.2021.01.026_bb0200","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.lfs.2018.01.020","article-title":"Cathepsin B inhibition attenuates cardiovascular pathology in mucopolysaccharidosis I mice","volume":"196","author":"Gonzalez","year":"2018","journal-title":"Life Sci"},{"key":"10.1016\/bs.pmbts.2021.01.026_bb0205","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.gene.2018.08.004","article-title":"CRISPR-Cas9-mediated gene editing in human MPS I fibroblasts","volume":"678","author":"de Carvalho","year":"2018","journal-title":"Gene"},{"key":"10.1016\/bs.pmbts.2021.01.026_bb0210","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejpb.2017.10.017","article-title":"Gene editing of MPS I human fibroblasts by co-delivery of a CRISPR\/Cas9 plasmid and a donor oligonucleotide using nanoemulsions as nonviral carriers","volume":"122","author":"Schuh","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"issue":"July","key":"10.1016\/bs.pmbts.2021.01.026_bb0215","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2018.08.031","article-title":"In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR\/Cas9 system","volume":"288","author":"Schuh","year":"2018","journal-title":"J Control Release"},{"issue":"1\u20132","key":"10.1016\/bs.pmbts.2021.01.026_bb0220","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41434-019-0113-4","article-title":"Neonatal nonviral gene editing with the CRISPR\/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice","volume":"27","author":"Schuh","year":"2020","journal-title":"Gene Ther"},{"issue":"1","key":"10.1016\/bs.pmbts.2021.01.026_bb0225","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/diseases5010006","article-title":"A prospective treatment option for lysosomal storage diseases: CRISPR\/Cas9 gene editing technology for mutation correction in induced pluripotent stem cells","volume":"5","author":"Christensen","year":"2017","journal-title":"Diseases"},{"key":"10.1016\/bs.pmbts.2021.01.026_bb0230","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40778-014-0007-8","article-title":"Genome editing: potential treatment for lysosomal storage diseases","volume":"1","author":"de Carvalho","year":"2015","journal-title":"Curr Stem Cell Rep"},{"issue":"5","key":"10.1016\/bs.pmbts.2021.01.026_bb0235","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.stem.2019.04.001","article-title":"Highly efficient and marker-free genome editing of human pluripotent stem cells by CRISPR-Cas9 RNP and AAV6 donor-mediated homologous recombination","volume":"24","author":"Martin","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/bs.pmbts.2021.01.026_bb0240","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.isci.2019.04.036","article-title":"CRISPR\/Cas9 genome engineering in engraftable human brain-derived neural stem cells","volume":"15","author":"Dever","year":"2019","journal-title":"iScience"},{"issue":"July","key":"10.1016\/bs.pmbts.2021.01.026_bb0245","article-title":"Overcoming the delivery problem for therapeutic genome editing: current status and perspective of non-viral methods","volume":"258","author":"Mashel","year":"2020","journal-title":"Biomaterials"},{"issue":"12","key":"10.1016\/bs.pmbts.2021.01.026_bb0250","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1080\/17425247.2016.1202235","article-title":"Nanotechnology applied to treatment of mucopolysaccharidoses","volume":"13","author":"Schuh","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"issue":"7","key":"10.1016\/bs.pmbts.2021.01.026_bb0255","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/14712598.2019.1607837","article-title":"An update on gene therapy for lysosomal storage disorders","volume":"19","author":"Nagree","year":"2019","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"10.1016\/bs.pmbts.2021.01.026_bb0260","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.3390\/ijms19092721","article-title":"In vivo genome editing as a therapeutic approach","volume":"19","author":"Ho","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"15","key":"10.1016\/bs.pmbts.2021.01.026_bb0265","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood-2014-12-615492","article-title":"In vivo genome editing of the albumin locus as a platform for protein replacement therapy","volume":"126","author":"Sharma","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/bs.pmbts.2021.01.026_bb0270","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.ymgme.2014.12.065","article-title":"ZFN-mediated genome editing of albumin safe harbor in vivo results in supraphysiological levels of human IDS, IDUA and GBA in mice","volume":"114","author":"DeKelver","year":"2016","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/bs.pmbts.2021.01.026_bb0275","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ymthe.2018.10.018","article-title":"ZFN-mediated in vivo genome editing corrects murine hurler syndrome","volume":"27","author":"Ou","year":"2019","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/bs.pmbts.2021.01.026_bb0280","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.ymthe.2018.03.002","article-title":"Dose-dependent prevention of metabolic and neurologic disease in murine MPS II by ZFN-mediated in vivo genome editing","volume":"26","author":"Laoharawee","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/bs.pmbts.2021.01.026_bb0285","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.omtm.2020.06.022","article-title":"Ready for repair? Gene editing enters the clinic for the treatment of human disease","volume":"18","author":"Ernst","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"10.1016\/bs.pmbts.2021.01.026_bb0290","first-page":"S68","article-title":"EMPOWERS: a phase 1\/2 clinical trial of SB-318 ZFN-mediated in vivo human genome editing for treatment of MPS I (Hurler syndrome)","volume":"126","author":"Harmatz","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1016\/bs.pmbts.2021.01.026_bb0295","first-page":"S104","article-title":"CHAMPIONS: a phase 1\/2 clinical trial with dose escalation of SB-913 ZFN-mediated in vivo human genome editing for treatment of MPS II (Hunter syndrome)","volume":"126","author":"Muenzer","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"6","key":"10.1016\/bs.pmbts.2021.01.026_bb0300","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ymthe.2020.03.018","article-title":"A highly efficacious PS gene editing system corrects metabolic and neurological complications of mucopolysaccharidosis type I","volume":"28","author":"Ou","year":"2020","journal-title":"Mol Ther"},{"issue":"9","key":"10.1016\/bs.pmbts.2021.01.026_bb0305","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nbt.4219","article-title":"Cas9-mediated allelic exchange repairs compound heterozygous recessive mutations in mice","volume":"36","author":"Wang","year":"2018","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/bs.pmbts.2021.01.026_bb0310","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1038\/s41467-019-11962-8","article-title":"Human genome-edited hematopoietic stem cells phenotypically correct mucopolysaccharidosis type I","volume":"10","author":"Gomez-Ospina","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/bs.pmbts.2021.01.026_bb0315","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1590\/1678-4685-gmb-2018-0174","article-title":"Clinical research challenges in rare genetic diseases in Brazil","volume":"42","author":"Giugliani","year":"2019","journal-title":"Genet Mol Biol"},{"issue":"10","key":"10.1016\/bs.pmbts.2021.01.026_bb0320","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nbt1018-907","article-title":"Sangamo's landmark genome editing trial gets mixed reception","volume":"36","author":"Sheridan","year":"2018","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/bs.pmbts.2021.01.026_bb0325","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/21678707.2020.1715208","article-title":"The potential of gene therapy for mucopolysaccharidosis type I","volume":"8","author":"Vera","year":"2020","journal-title":"Expert Opin Orphan Drugs"}],"container-title":["Progress in Molecular Biology and Translational Science","Curing Genetic Diseases Through Genome Reprogramming"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117321000375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117321000375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T02:06:17Z","timestamp":1724551577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117321000375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9780323853019"],"references-count":64,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2021.01.026","relation":{},"ISSN":["1877-1173"],"issn-type":[{"type":"print","value":"1877-1173"}],"subject":[],"published":{"date-parts":[[2021]]}}}